WT1 expression in normal and neoplastic cranial and peripheral nerves is independent of grade of malignancy

Cancer Biomarkers

Volumn 7, Issue 2, 2010, Pages 73-77

  Schittenhelm, Jens ^a   Thiericke, John ^a   Nagel, Christoph ^a   Meyermann, Richard ^a   Beschorner, Rudi ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

MPNST; neurofibroma; schwannoma; WT1

Indexed keywords

BIOLOGICAL MARKER; CYTOPLASM PROTEIN; WT1 PROTEIN;

ADULT; ARTICLE; BRAIN TUMOR; CANCER GRADING; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CRANIAL NERVE; FEMALE; GLIA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; PERIPHERAL NERVE; PHAKOMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHWANN CELL; TUMOR CELL; TUMOR GROWTH; UPREGULATION;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CRANIAL NERVE NEOPLASMS; CRANIAL NERVES; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE SHEATH NEOPLASMS; NEURILEMMOMA; NEUROFIBROMA; PERIPHERAL NERVES; WT1 PROTEINS; YOUNG ADULT;

EID: 78650587106     PISSN: 15740153     EISSN: None     Source Type: Journal    
DOI: 10.3233/CBM-2010-0149     Document Type: Article

References (31)

1. A.J. Buckler, J. Pelletier, D.A. Haber et al., Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development, Mol Cell Biol 11 (1991), 1707-1012.
2. Z.Y.Wang, Q.Q. Qiu and T.F. Deuel, TheWilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains, J Biol Chem 13 (1993), 9172-9175.
3. N.D. Hastie, The genetics of Wilms' tumor - a case of disrupted development, Annu Rev Genet 28 (1994), 523-558.
4. O.L. Caballero, S.J. de Souzab, R.R. Brentania et al., Alternative spliced transcripts as cancer markers,Dis Markers 17 (2001), 67-67.
5. Y. Han, S. SanMarina, J. Liu et al., Transcriptional activation of cmyc protooncogene by WT1 protein, Oncogene 23 (2004), 6933-6941.
6. S.M. Hewitt, S. Hamada, T.J. McDonnell et al., Regulation of the protooncogenes bcl2 and cmyc by the Wilms' tumor suppressor gene WT1, Cancer Res 15 (1995), 5386-5389.
7. J. Hartkamp and S.G. Roberts, The role of the Wilms' tumorsuppressor protein WT1 in apoptosis, Biochem Soc Trans 36 (2008), 629-631.
8. L. Yang, Y. Han, F. Suarez Saiz et al., A tumor suppressor and oncogene: The WT1 story, Leukemia 5 (2007), 868-876.
9. T. Ueda, Y. Oji, N. Naka et al., Overexpression of the Wilms' tumor gene WT1 in human bone and softtissue sarcomas, Cancer Sci 94 (2003), 271-276.
10. J. Schittenhelm, R. Beschorner, P. Simon et al., Diagnostic value of WT1 in neuroepithelial tumors, Neuropathol Appl Neurobiol 35 (2009), 69-81.
11. H.D. Menssen, E. Bertelmann, S. Bartelt et al., Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens, J Cancer Res Clin Oncol 126 (2000), 226-232.
12. J.H. Li and Y.G. Man, Dual usages of single Wilms' tumor 1 immunohistochemistry in evaluation of breast tumors: A preliminary study of 30 cases, Cancer Biomarkers 5 (2009), 109-116.
13. B. S. Ducatman, B.W. Scheithauer, D.G. Piepgras et al., Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases, Cancer 57 (1986), 2006-2021.
14. J.J. Lewis andM.F. Brennan, Soft tissue sarcomas, Curr Probl Surg 33 (1996), 817-872.
15. C. Hagel, U. Zils, U. Peiper et al., Histopathology and clinical outcome of NF1associated vs. sporadic malignant peripheral nerve sheath tumors, J Neurooncol 82 (2007), 187-192.
16. J.M. Coindre, M. Trojani, G. Contesso et al., Reproducibility of a histopathologic grading system for adult soft tissue sarcoma, Cancer 15 (1986), 306-309.
17. B. Scheithauer, D.N. Louis, S. Hunter et al., Tumors of the cranial and paraspinal nerves, in: WHO Classification of Tumors of the Central Nervous System, D. Louis, H. Ohgaki, O. Wiestler andW. Cavenee, eds, IARC press 2007, pp. 152-162.
18. W. Cai, A. Kassarjian, M.A. Bredella et al., Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination onwholebodyMRimages, Radiology 250 (2009), 665-673.
19. Y. Oka, A Tsuboi, F. Fujiki et al., WT1 peptide vaccine as a paradigm for "cancer antigenderived peptide"based immunotherapy for malignancies: Successful induction of anticancer effect by vaccinationwith a single kind ofWT1 peptide, Anticancer Agents Med Chem 9 (2009), 787-797.
20. A. Coosemans, P. Moerman, I. Vergote et al., Wilms' tumor gene 1 (WT1) overexpression in neurons in deep endometriosis: A pilot study, Fertil Steril 91 (2009), 1441-1444.
21. M. Samii and C. Matthies, Management of 1000 vestibular schwannomas (acoustic neuromas): Hearing function in 1000 tumor resections, Neurosurgery 40 (1997), 248-260.
22. J. Schittenhelm, R. Beschorner, P. Simon et al., Diagnostic value of WT1 in neuroepithelial tumours, Neuropathol Appl Neurobiol 35 (2009), 69-81.
23. T. Jomgeow, Y. Oji, N. Tsuji et al., Wilms' tumor gene WT1 17AA()/ KTS() isoform induces morphological changes and promotes cell migration and invasion in vitro, Cancer Sci 97 (2006), 259-270.
24. G.H. Kang, K.M. Kim, J.H. Noh et al., WT1 expression in gastrointestinal stromal tumours, Pathology 42 (2010), 54-57.
25. S.Mundlos, J. Pelletier, A. Darveau et al., Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues, Development 119 (1993), 1329-1341.
26. N. Wagner, J.F. Michiels, A. Schedl et al., The Wilms' tumor suppressor WT1 is involved in endothelial cell proliferation and migration: Expression in tumor vessels in vivo, Oncogene 26 (2008), 3662-3672.
27. J. Timar, L. Meszaros, Z. Orosz et al., WT1 expression in angiogenic tumors of the skin, Histopathology 47 (2005), 67-73.
28. J. Schittenhelm, T. Psaras, J. Honegger et al., No evidence forWT1 involvement in a betacateninindependent activation of the Wnt signaling pathway in pituitary adenomas, Endocr Pathol 20 (2009), 158-162.
29. S. Izumoto, A. Tsuboi, Y. Oka et al., Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme, J Neurosurg 108 (2008), 963-971.
30. S. KumarSingh, K. Segers, U. Rodeck et al., WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, celltype transition, and prognosis. J Pathol 181 (1997), 67-74.
31. U. Keilholz, A. Letsch, A. Busse et al., A clinical and immunologic phase 2 trial ofWilms tumor gene product 1 (WT1) peptide vaccination in patients with AML andMDS, Blood 25 (2009), 6541-6548.